Investing.com — After one of the most contentious proxy battles in recent medical-device history, STAAR Surgical Company () is beginning to prove that its standalone strategy can work. Last week, the Lake Forest-based leader in lens-based refractive surgery reported first-quarter financial results that came in well ahead of Wall Street expectations.
The corporate milestone signals a strong operational turnaround just months after shareholders blocked a proposed acquisition by industry giant Alcon. The return to stability has already been rewarded by public markets, pushing the stock price to $33/share by May 20, 2026, comfortably above Alcon’s final sweetened buyout offer of $30.75.
Weigh the fair value of STAA stock by upgrading to InvestingPro – get 55% off today
Strong Rebound Quarter
The medical device maker reported first-quarter GAAP earnings per share of $0.10, doubling the consensus analyst estimate of $0.05. Net sales for the quarter reached $93.5 million, marking a 119.6% year-over-year surge and exceeding analyst expectations of $78.74 million.
Prior to this rebound, STAAR had spent more than a year heavily embattled by falling demand and severe distributor inventory build-ups in China. In early 2025, the company curtailed shipments to Chinese distributors to allow them to work through excess channel inventory, causing Q1 2025 net sales to crash to $42.6 million.
Amid these operational headwinds, Alcon launched an unsolicited $1.5 billion buyout offer at $28.00 per share in August 2025. Although Alcon later sweetened the deal to a $1.6 billion final offer of $30.75 per share in December 2025, activist investor Broadwood Partners rallied shareholders to resist the takeover.
STAAR and Alcon terminated the deal on January 6, 2026, after a majority of stockholders voted against the merger in a special meeting, prompting a comprehensive governance reset and a settlement with Broadwood. Following the pivotal shareholder revolt, the board added three directors and installed Warren Foust and Deborah Andrews as interim Co-CEOs to implement a standalone strategy.
Execution Over Distraction
The interim leadership immediately targeted operational excellence, prioritizing revenue growth, profit expansion, and product innovation. In their first letter to shareholders, the interim Co-CEOs wrote, “We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion, and we expect to advance Product Innovation over the balance of the year.”
Reflecting on his first 100 days steering the company through this transition, Co-CEO Warren Foust emphasized the internal cultural shift in statements made to Investing.com:
“STAAR has always had a strong culture, but I believe it has become even stronger over the last several months. I’m incredibly proud of how our teams around the world came together with resilience and professionalism during a period of uncertainty. Today, there is real energy and alignment across the organization as our teams focus on the opportunities ahead and the true earning power of the business is beginning to reveal itself as many of the short-term disruptions move behind us.
The key was creating clarity and reducing distractions so our teams could focus on what they do best. We have incredibly talented people around the world who are advancing refractive surgery through our Collamer lens technology, and once the organization regained alignment around priorities, the focus naturally returned to execution, innovation and supporting customers and patients.”
The structural reset quickly translated into financial performance, yielding an operating income of $8.0 million compared to an operating loss of $(57.4) million in the prior year’s quarter. Adjusted EBITDA swung dramatically to a profit of $24.4 million, far outpacing the $26.3 million loss in 2025’s first quarter.
Co-CEO Deborah Andrews noted to Investing.com in a statement that this financial discipline directly underpins the company’s long-term independence:
“We moved forward by taking decisive cost actions, staying focused on execution, and maintaining confidence in the long-term strength of our ICL franchise. As temporary headwinds eased, demand returned and our leaner operating model drove strong profitability. This quarter reinforces that STAAR has the technology, discipline, and execution to succeed as a standalone company and create long-term shareholder value.”
Regional Dynamics and Market Evolution
A deep dive into regional metrics reveals that the recovery was spearheaded by China, where net sales reached $47.4 million on the back of the successful commercial launch of the premium EVO+ ICL lens. In their shareholder letter, the Co-CEOs noted that distributor inventory levels in China have stabilized to targeted ranges, ensuring that current sell-in matches organic patient demand.
In the United States, STAAR crossed a key milestone by generating more than $6 million in quarterly net sales, growing 22% year-over-year. This domestic expansion was achieved despite persistent sluggishness in the broader U.S. refractive surgery market, where LASIK procedures have experienced compounding declines.
According to data from the Refractive Surgery Council cited by Foust on the company’s earnings call, U.S. laser vision correction surgical volumes fell around 7% in Q1 2026, continuing a sharp downward trajectory where volumes plummeted around 15% on a year-over-year basis.
As preferences shift toward reversible, lens-based solutions like STAAR’s flagship EVO ICL, clinical data cited by Dr. Matthew Sharpe of SharpeVision shows that implantable collamer lenses (ICLs) deliver a 93.3% rate of vision improvement compared to 88.3% for standard corneal laser correction.
Strategic Pivots and Future Outlook
To capture a larger share of the domestic market, STAAR is actively shifting its marketing strategy. The company has focused on targeted investments in markets where it believes it can have the greatest impact. In its recent shareholder letter, the Co-CEOs highlighted the performance of this shift, stating, “We also are encouraged by the impact of our updated marketing strategy, which focuses on surgeons who are prioritizing EVO ICL in their practices.”
Concurrently, the company is progressing with a multi-year rollout of a new Enterprise Resource Planning (ERP) platform. Although the transition is still in its early phases, the shareholder letter noted that internal operations have faced minimal disruptions. Over time, the platform is expected to streamline corporate visibility and scaling.
The infrastructure upgrade, alongside stronger growth metrics and expanded regulatory approvals, including a recent FDA label expansion for patients from ages 45-60, underpins the company’s long-term runway. Ultimately, STAAR is positioning its lens-based portfolio in hopes of capturing a massive addressable market, with myopia (nearsightedness) projected to affect half the world’s population by 2050.
Analyst Reactions and Headwinds
Despite these operational triumphs, the wider analyst community continues to exhibit measured caution regarding the long-term durability of the company’s turnaround. While Wedbush analyst Michael Piccolo upgraded the stock to an Outperform rating with a bullish target price of $40.00, the overall consensus remains a Hold with an average target price of $29.67, according to data from 11 analysts compiled by Investing.com.
Firms like Stifel and Piper Sandler adjusted their target prices upward to $31.00 and $33.00, respectively, but both maintained Neutral ratings due to a lack of visibility. “We still wrestle with the underlying visibility in the business and are content remaining on the sidelines for now,” said Piper analyst Adam Maeder in a post-earnings note.
“Although we await better visibility into numbers, STAA is clearly on stronger footing as the end market and inventory in China improves/normalizes,” Stifel analyst Thomas Stephan noted.
Piccolo, however, cited the strong results as indicative of an “inflection point for a full China rebound.” He noted that the company has the potential to exceed Wedbush’s bull case scenario in the coming quarters, adding that incremental China recovery progress is likely to lead to valuation re-rating and multiple expansion back to historical levels.
Macroeconomic volatility and geopolitical conflicts in the Middle East have presented near-term headwinds, leading the company to refrain from issuing formal full-year guidance. Disruptions in the region cost the company nearly $2 million in first-quarter sales. The current U.S.-Iran conflict has triggered a global energy shock, as the closure of the Strait of Hormuz continues to roil consumers and lift inflationary pressures.
From a macroeconomic perspective, the return of Chinese demand could ultimately prove less vulnerable to the global energy crisis than other key medical device markets. On one hand, China maintains large strategic oil reserves and continues to expand domestic electric vehicle adoption, potentially insulating consumer demand from fuel-driven inflationary shocks relative to more oil-sensitive economies.
However, near-term conditions remain highly fluid. Geopolitical tracking data from a recent Morning Consult report indicated a brief 5-point week-over-week dip in Chinese consumer confidence following initial price shocks from the Middle East conflict, highlighting that Chinese consumers are not immune to jitters when global energy prices spike.
Management remained cautious when discussing China, noting in the shareholder letter that “while macroeconomic signals remain mixed, underlying demand for refractive procedures continues to grow at a moderate pace.”
While skeptics question the durability of STAAR’s operational recovery, the medical device maker’s consumer demographics could potentially provide a buffer against macroeconomic deterioration, especially in the U.S. Refractive surgery demand has historically been anchored by patients with higher disposable income who remain somewhat insulated from inflationary pressures, as well as health-conscious consumers who prioritize clinical spending over traditional retail items. Additionally, the company benefits from the immense value consumers place on their eyesight, offering a more resilient base even as broader discretionary budgets tighten. According to a 2022 survey from NVISION, 77% of Americans value their vision over all other senses.
On another macroeconomic front, to protect its manufacturing flow from shifting trade policies, STAAR is leveraging its facility in Nidau, Switzerland. This localized footprint ensures that 100% of the lenses shipped to China completely bypass standard US-China tariff exposures. However, while the manufacturing pivot successfully eased investor anxiety over 2025’s whipsawing tariff friction, it does little to alleviate broader market concerns regarding the global energy shock.
While Wall Street continues to debate the long-term outlook for the stock, STAAR’s immediate operational execution has effectively challenged the bearish narrative surrounding its post-proxy viability. By securing its supply chain, normalizing channel inventory, and capturing market share in a declining refractive landscape, the company has begun to reinforce the commercial viability of its standalone strategy.